Details

Autor(en) / Beteiligte

• Rausch, Magdalena
• Dyson, Paul J.
• Nowak‐Sliwinska, Patrycja

Titel

Recent Considerations in the Application of RAPTA‐C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies

Ist Teil von

• Advanced therapeutics, 2019-09, Vol.2 (9), p.n/a

Erscheinungsjahr

2019

Quelle

Wiley Online Library - AutoHoldings Journals

Beschreibungen/Notizen

• The organometallic ruthenium(II) [Ru(arene)Cl2PTA] PTA ‐ 1,3,5‐triaza‐7‐phosphaadamantane compound, RAPTA‐C, represents an innovative anti‐cancer therapeutic and a better‐tolerated alternative to platinum (Pt)‐based chemotherapeutic drugs in the treatment of cancer. RAPTA‐C exhibits anti‐metastatic, anti‐angiogenic, and anti‐tumoral activities through protein and histone–deoxyribonucleic acid alterations. In comparison to other ruthenium‐based drugs, which have been recently evaluated in clinical trials, RAPTA‐C is strikingly competitive, especially when administered in combination with other targeted drugs. In this review, the uniqueness of RAPTA‐C as an anti‐cancer chemotherapeutic compared to metal‐based drugs under clinical evaluation and those approved by the Food and Drug Administration is emphasized; specifically, comparing the application of RAPTA‐C to platinum‐based drugs, for example, cisplatin and oxaliplatin, as well as to prominent ruthenium‐based compounds, such as NAMI‐A imidazolium‐trans‐tetrachloro(dimethylsulfoxide) imidazoleruthenium(III) and trans‐[tetrachlorobis (1Hindazole) ruthenate(III)] (KP1019)/(N)KP1339 (N)KP1339 ‐ sodium. Additionally, the possible correlation between RAPTA‐C and immune response modulation, as well as potential applications of RAPTA‐C in combination with immune therapeutic regimens, is highlighted. RAPTA‐C represents an innovative therapeutic for the treatment of cancer. In contrast to platinum‐based drugs as well as other ruthenium‐based regimens, RAPTA‐C exhibits a unique set of properties leading to anti‐cancer activity. RAPTA‐C has the potential to be applied in combination with targeted therapies, HDAC inhibitors, or immune therapeutics and possibly enter clinical evaluation in the future.